| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a0c3e4b714908382e152c4ee0b8ed0b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate |
2020-07-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cabd17ed59e613fd3c4449097bdefeb7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d0f258d09c8085c674194e02b6c31a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1ae4a3be5e6607410d07badff8cce5bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_94f7df3f376576328e8b6a316b5f2a48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e748ddfd3247d354d366753064436656
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_45eb05cb608d286ddca63386f987510e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7b97238619b1337be100c8cebe6e0924
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6849d91c7c56bcb52b789ed188f69f41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88162e6a128ae8ca27012e630fd25ef3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0e492e8b90dc62cca768edf9784067f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b224c450a56f3a78082330014e47e650 |
| publicationDate |
2020-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2020210278-A1 |
| titleOfInvention |
Use of pyrazolopyrimidine derivatives for the treatment of pi3kdelta related disorders |
| abstract |
The present application provides methods of treating PBK6 related disorders using ncompounds of Formula (I): or pharmaceutically acceptable salts thereof. nCy nR4 OR2 nN'N nH 2N |
| priorityDate |
2013-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |